Literature DB >> 7766946

Loss of neurotransmitter receptors by hyperphenylalaninemia in the HPH-5 mouse brain.

F A Hommes1.   

Abstract

The binding of the muscarinic acetylcholine antagonist quinuclinidylbensilate to its specific receptors was measured by quantitative autoradiography in the brain of the HPH-5 mouse, a phenylalanine hydroxylase-deficient mouse mutant, as a model for human PKU. Three types of response to a hyperphenylalaninemic condition were observed: no effect as in the putamen; a gradual decrease over time such as in several areas of the cerebral cortex and the hippocampus; a transient increase, followed by a decrease, such as in the frontal area of the cerebral cortex. Of particular significance is the effect on the CA1 and CA3 layer of the hippocampus, since this structure has been implicated in the acquisition and storage of long-term memory. Hyperphenylalaninemia leads to a decrease in neurotransmitter receptor density and, therefore, to a decrease in connectivity, which may form the basis for the mental retardation in this condition.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7766946     DOI: 10.1111/j.1651-2227.1994.tb13469.x

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  3 in total

1.  Derangement of the dopaminergic system in phenylketonuria: study of the event-related potential (P300).

Authors:  V Leuzzi; S Seri; A Cerquiglini; C Carducci; C Carducci; I Antonozzi
Journal:  J Inherit Metab Dis       Date:  2000-06       Impact factor: 4.982

2.  Regression of neuropsychological deficits in early-treated phenylketonurics during adolescence.

Authors:  J Weglage; M Pietsch; J Denecke; A Sprinz; R Feldmann; M Grenzebach; K Ullrich
Journal:  J Inherit Metab Dis       Date:  1999-08       Impact factor: 4.982

3.  Immune Tolerance in Mytilus galloprovincialis Hemocytes After Repeated Contact With Vibrio splendidus.

Authors:  Magalí Rey-Campos; Rebeca Moreira; Marco Gerdol; Alberto Pallavicini; Beatriz Novoa; Antonio Figueras
Journal:  Front Immunol       Date:  2019-08-09       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.